Clinical Trial Update: Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update exploring neoadjuvant Carilizumab and Apatinib for recurrent high-grade glioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• High-grade Glioma

Drugs mentioned

• Apatinib (apatinib)
• Carilizumab (Carilizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Neoadjuvant Therapy, Carilizumab | Phase 2 | Status: UNKNOWN